Viewing Study NCT06093503

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 7:12 PM
Ignite Modification Date: 2026-02-21 @ 6:45 PM
Study NCT ID: NCT06093503
Status: WITHDRAWN
Last Update Posted: 2024-06-26
First Post: 2023-10-17
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein
Sponsor: AbbVie
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non-Small Cell Lung Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Non-Small Cell Lung Cancer View
None Telisotuzumab Vedotin View
None ABBV-399 View
None Osimertinib View
None Cisplatin View
None Carboplatin View
None Pemetrexed View
None c-Met View
None NSCLC View
None Teliso-V View
None TeliMET NSCLC-03 View